Ocular Disorder Treatment with Amino Isoquinolinyl Amide Compounds

According to GlobalData’s company profile on Aerie Pharmaceuticals, was a key innovation area identified from patents.

A recently granted patent (Publication Number: US11891376B2) discloses a method for treating ocular disorders using a specific compound of Formula (I). The method involves administering this compound, which can also be a compound of Formula (II) or (III), in a therapeutically effective amount to a subject in need. The compound’s structure includes various substituents such as H, halo, —CN, —C1-3 alkyl, —C1-3 alkoxyl, —C1-3 haloalkyl, and —C1-3 haloalkoxyl, providing flexibility in its application.

Furthermore, the patent covers methods for reducing intraocular pressure and modulating kinase activity in cells using the same compound of Formula (I). The administration of the compound can be done topically to the eye or eyelid of the subject, making it a convenient treatment option for ocular disorders like glaucoma, inflammatory eye diseases, neurodegenerative eye diseases, diabetic eye diseases, wet age-related macular degeneration, and dry age-related macular degeneration. The compound’s versatility and potential to target kinase activity in cells, particularly in human subjects, highlight its therapeutic value in the field of ophthalmology.

To know more about GlobalData’s detailed insights on Aerie Pharmaceuticals, buy the report here.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies